References
- Long DM. IMS Health. Presentation at the National Association of Specialty Pharmacy (NASP) Annual Meeting and Expo. Orlando, FL. October 1-3, 2014
- Fein AJ. The 13 Fastest-Growing, Private Specialty Pharmacies. Philadelphia, PA: Pembroke Consulting, Inc., 2012. http://www.drugchannels.net/2012/10/the-13-fastest-growing-private.html. Accessed September 24, 2015
- Fein AJ. 2013 Pharmacy Market Share for Specialty Drugs—and the Biggest Players. Philadelphia, PA: Pembroke Consulting, Inc., 2014. http://www.drugchannels.net/2014/03/2013-pharmacy-market-share-for.html. Accessed October 16, 2014
- Berger ML, Bingefors K, Hedblom E, et al. (Manging Editor, Smith MD). Health Care Cost, Quality, and Outcomes: ISPOR Book of terms. Lawrenceville, NJ: International Society for Pharmacoeconomics and Outcomes Research, 2003. http://www.ispor.org/terminology/. Accessed September 12, 2014
- Drummond M, Brown R, Fendrick AM, et al. Use of pharmacoeconomics information–report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 2003;6:407–16
- Berger ML, Mamdani M, Atkins D, et al. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report–Part I. Value Health 2009;12:1044–52
- Johnson ML, Crown W, Martin BC, et al. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report–Part III. Value Health 2009;12:1062–73
- McGhan WF, Al M, Doshi JA, et al. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. Value Health 2009;12:1086–99
- SOVALDI® (sofosbuvir). Foster City, CA: Gilead Sciences, Inc., 2015. http://www.sovaldi.com/. Accessed December 29, 2014
- A New Chronic Hepatitis C Treatment | OLYSIO™ (simeprevir). Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP, 2014. http://www.olysio.com/. Accessed December 29, 2014
- AVBCC 2013 Steering Committee: Co-Chairs, Zweigenhaft B, Bosserman L, Kenney JT Jr, et al. Defining value in cancer care: AVBCC 2013 Steering Committee Report. Am Health Drug Benefits 2013;6:236–46
- Bickmore TW, Schulman D, Sidner C. Automated interventions for multiple health behaviors using conversational agents. Patient Educ Couns 2013;92:142–8
- HEDIS® and Quality Compass®. Washington, DC: National Committee for Quality Assurance, http://www.ncqa.org/HEDISQualityMeasurement/WhatisHEDIS.aspx. Accessed November 29, 2014
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Guidelines. Washington, DC: NCQA, 2014. http://www.nccn.org/professionals/default.aspx. Accessed November 29, 2014
- Herceptin (trastuzumab). South San Francisco, CA: Genentech Inc., 2014. http:/www.herceptin.com. Accessed November 29, 2014
- Perjeta (pertuzumab). South San Francisco, CA: Genentech Inc., 2014. http://www.perjeta.com/. Accessed November 29, 2014
- Whole Body PET Scan Cost and Procedure Information. Pensacola, FL: New Choice Health, Inc., 2014. http://www.newchoicehealth.com/procedures/whole-body-pet-scan. Accessed 12/5/14
- Goldberg L, Zitter Health Insights. Presentation at the National Association of Specialty Pharmacy (NASP) Annual Meeting and Expo. Orlando, FL. October 1-3, 2014
- Goldberg, L. The Managed Care Biologics and Injectables Index: Spring 2014. Livingston, NJ: Zitter Health Insights, 2014. p. 57
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Rockville, MD: AIDSinfo, 2014. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf Treatment Goals, page D1. Accessed October 16, 2014
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Rockville, MD: AIDSinfo, 2014. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf Adherence, page K1-2. Accessed October 16, 2014
- Atripla. Princeton, NJ: Bristol-Myers Squibb Company. http://www.atripla.com/index.aspx. Accessed October 27, 2014
- Nachega JB, Parienti J, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV Infection: a meta-analysis of randomized controlled trials. Clin Infect Dis 2014;58:1297–307
- Ryan B. FDA Approves Gilead’s Hep C Drug Harvoni (Ledipasvir/Sofosbuvir), by Benjamin Ryan October 10, 2014. Hep Web Exclusives. New York (NY): Smart + Strong. http://www.hepmag.com/articles/Harvoni_approval_2502_26290.shtml. Accessed October 27, 2014
- FDA Approves Olysio-Sovaldi Hep C Combo. New York, NY: Smart + Strong. http://www.aidsmeds.com/articles/Olysio_Sovaldi_approval_1667_26373.shtml. Accessed November 30, 2014
- Brook RA, Kleinman NL, Su J, et al. Absenteeism and productivity among employees being treated for Hepatitis C. Am J Manag Care 2011;17:657–64
- Baran RW, Samp JC, Walker DR, et al. Costs and absence of HCV-infected employees by disease stage. J Med Econ 2015;5:1–13
- Goldberg L. Hep C Impact Monitor. Livingston, NJ: Zitter Health Insights, 2014. http://zitter.com/insights-we-offer/hep-c-impact-monitor/. Accessed December 30, 2014
- Medications. New York, NY: The National Multiple Sclerosis Society, 2014. http://www.nationalmssociety.org/Treating-MS/Medications. Accessed April 27, 2015
- Hsiao C-J, Hing E, Ashman J. Trends in electronic health record system use among office-based physicians: United States, 2007–2012. National Health Statistics Reports. Hyattsville, MD: Centers for Disease Control and Prevention, 2014. Number 75. http://www.cdc.gov/nchs/data/nhsr/nhsr075.pdf. Accessed December 29, 2014
- Charles D, Gabriel M, Furukawa MF. Adoption of Electronic Health Record Systems among U.S. Non-federal Acute Care Hospitals: 2008-2013. ONC Data Brief, No. 16. Washington, DC: Office of the National Coordinator for Health Information Technology, May 2014. http://www.healthit.gov/sites/default/files/oncdatabrief16.pdf. Accessed December 30, 2014
- Palma G. Electronic Health Records: The Good, the Bad and the Ugly. Becker’s Health IT and CIO Review. Chicago, IL: Becker's Healthcare, 2013. http://www.beckershospitalreview.com/healthcare-information-technology/electronic-health-records-the-good-the-bad-and-the-ugly.html. Accessed August 28, 2015
- Physician Supply and Demand Through 2025: Key Findings. Washington, DC: Association of American Medical Colleges, https://www.aamc.org/download/426260/data/physiciansupplyanddemandthrough2025keyfindings.pdf. Accessed June 25, 2015
- Best Electronic Medical Records Software | 2015 Reviews of the Most. Arlington, VA: Capterra Inc., 2014. http://www.capterra.com/electronic-medical-records-software/. Accessed December 30, 2014
- Dieterich D, Bacon BR, Flamm SL, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 2014;60:220A
- Pawlotsky JM, Aghemo A, Back D, et al. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;63:199–236